Carolina Distinguished Professor
Chair, Department of Pathology, Microbiology and Immunology
University of South Carolina
研究方向
The primary research interests of Dr. Mitzi Nagarkatti’s lab include Cancer Immunology and Immunotherapy, Biodefense, Immunopharmacology, Immunotoxicology, and Complementary and Alternative Medicine.
科研成果
Dr. Mitzi Nagarkatti's research was strongly supported by the National Institutes of Health (NIH), the Natural Science Foundation of the United States and the American Cancer Society. Dr. Mitzi Nagarkatti's research achievements have been recognized both domestically and internationally. He has made many reports at important international and domestic conferences and won many national and international awards. So far, more than 200 papers have been published in top international magazines.
業(yè)績或榮譽(yù)
Interleukin-2 (IL-2) has been shown to be effective in the treatment of certain types of cancer including human melanomas and renal cell carcinomas. However, IL-2 therapy is accompanied by severe life-threatening toxicity characterized by endothelial cell injury leading to vascular leak syndrome (VLS). We are interested in reducing the toxicity associated with such therapy by preventing the interaction of a molecule known as CD44 present on cytotoxic lymphocytes with their ligands found on endothelial cells. Our studies are aimed at addressing the role of various CD44 isoforms present on the lymphocytes that may be involved in endothelial cell injury and tumor rejection.
